Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310655 | 1.00 | ADRB2 (0.40) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL385179 | 0.91 | ADRB2 (0.39) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL5999450 | 0.91 | ADRB2 (0.39) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL18016231 | 0.89 | ADRB2 (0.39) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL776314 | 0.89 | ADRB2 (0.39) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL14617522 | 0.89 | ADRB2 (0.39) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL384325 | 0.89 | ADRB2 (0.39) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL3586934 | 0.89 | ADRB2 (0.39) | ADRB2ADRB1ADORA3DRD2DRD1 | |
| SCHEMBL3990604 | 0.85 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL17979457 | 0.85 | ADRB2 (0.49) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | ADRB2 16/4885ADRB1 15/4885ADORA3 534/4885 |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | ADRB2 13/4885ADRB1 12/4885ADORA3 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.